Search the Newsreel

Privia Health (NASDAQ: PRVA) lifts Q2 2026 revenue, margins and expands credit line

Privia Health Group, Inc. (NASDAQ: PRVA) reported significant financial growth for Q2 2026, with revenue increasing to $632.6 million and net income rising to $9.0 million. The company also expanded its revolving credit facility to $250 million with no outstanding borrowings, demonstrating strong liquidity. …

Chorus Aviation stock flying high on Q2 2026 financial results | 2026-08-05 | Investing News

Privia Health (NASDAQ:PRVA) Surprises With Q2 CY2026 Sales

Privia Health (NASDAQ:PRVA) Surprises With Q2 CY2026 Sales Healthcare tech company Privia Health Group (NASDAQ:PRVA) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 21.4% year on year to $632.6 million. Its non-GAAP profit was $0.19 per share. Is now …

Via Transportation, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Via Transportation, Inc. Raises Earnings Guidance for the Full Year 2026

Joby Stock Rises After Sales Beat Expectations

Joby Aviation topped second-quarter sales estimates and raised its 2026 revenue outlook, but investors remain focused on certification and the launch of its electric air-taxi service. Continue Reading

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

IQVIA Holdings Inc (IQV) surges as weekly volume screen lights up

The healthcare research-services stock closed at 235.02 USD after a broad rebound across one-, four- and twelve-week measures.

Earnings Flash (VIA) Via Transportation, Inc. Posts Q2 Adjusted Loss $0.01 per Share, vs. FactSet Est of $-0.02

Viatris: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose für 2026 angehoben

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, …

Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60

Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.

Privia Health beats Q2 estimates, issues 2026 guidance

Privia Health Group, Inc. (NASDAQ:PRVA) reported strong second-quarter results, exceeding analyst expectations with adjusted EPS of $0.19 and revenue of $632.6 million. The company also issued its first fiscal year 2026 revenue guidance, projecting between $2.35 billion and $2.45 billion, with the midpoint slightly …

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its …

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow, Inc. NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from …

Viasat (VSAT) SVP, Pres Commercial Benjamin Palmer Sells 2,400 Shares

Viasat's SVP, President of Commercial, Benjamin Palmer, sold 2,400 shares of VSAT on August 3, 2026, for approximately $181,104. This transaction adds to a trend of consistent insider selling over the past year, with no insider buys. GuruFocus data indicates the stock is significantly …

Privia Health Group Reports Second Quarter 2026 Results, Raises Full-Year Guidance

Privia Health Group (PRVA) announced strong second-quarter 2026 financial results, with net income rising 236.7% to $9.0 million and adjusted EBITDA increasing 29.1% to $37.4 million. Total revenue grew 21.4% to $632.6 million, leading the company to raise its full-year 2026 guidance across all …

Joby Aviation Climbs 9% on Raised Guidance as Archer Aviation, EHang Sit Out the eVTOL Rally

Joby Aviation's stock surged 9% after the company raised its 2026 revenue guidance to $115M-$125M, beating Q2 estimates with $38.6 million in revenue and reporting strong FAA certification progress. In contrast, competitors Archer Aviation and EHang Holdings saw their stocks remain flat or decline, …

Cooper Investors PTY Ltd. Raises Holdings in Ferrovial SE $FER

Cooper Investors PTY Ltd. significantly increased its stake in Ferrovial SE (NASDAQ:FER) by 23.7% in the second quarter, now holding 129,165 shares valued at approximately $8.86 million, making Ferrovial its 10th largest holding. Other institutional investors also raised their positions, with Marshall Wace LLP …

JOBY Rises Premarket As It Moves Closer To Electric Air Taxi Launch With Texas Flights — 'We Are Closer Than We’ve Ever Been'

Joby Aviation's stock rose premarket following its Q2 earnings report, which showed increased revenue and improved year-on-year losses, alongside a strong cash position. The company plans to initiate electric air taxi pilot flights in Texas next month, marking a significant step towards commercial operations. …

Privia Health Group, Inc. Stock 12‑Month Price Target Raised to $32.11, Implies 35% Upside

Privia Health Group, Inc.'s average stock price target has increased from $31.89 to $32.11, according to estimates from 18 analysts. This updated target implies a 35% potential upside based on the Aug. 4 closing price, with forecasts ranging from $24 to $40 per share. …

Privia Health (Nasdaq: PRVA) lifts 2026 outlook after strong Q2 results

Viatris (Nasdaq: VTRS) grows Q2 revenue, raises 2026 outlook

Viasat (VSAT) Stock Drops As Losses Cloud Its Cash Flow Progress

Joby Aviation (JOBY) Stock Rises As Revenue Builds But Losses Persist

Zevia PBC (ZVIA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Zevia PBC 2026 Q2 - Results - Earnings Call Presentation (NYSE:ZVIA) 2026-08-06

Key Points Interested in Zevia PBC? Here are five stocks we like better. Q2 sales increased 1.1% to $45 million, while adjusted EBITDA improved to approximately $0.5 million from $0.2 million a year earlier. Gross margin edged up to 48.9%, although higher aluminum costs …

Via Transportation (NASDAQ: VIA) lifts Q2 revenue 27% and nears breakeven

Privia Health (PRVA) Misses Q2 Earnings Estimates

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Chorus Aviation (CHR) Gets a Buy from Stifel Nicolaus

Royal Bank Of Canada Forecasts Strong Price Appreciation for Chorus Aviation (TSE:CHR) Stock

Weekly Recap: Rivian (RIVN) Q2 results and US sourcing shift

Rivian (RIVN) reported Q2 revenue of $1.66 billion and a gross profit of $179 million, but still incurred a net loss of approximately $835 million. The company produced 12,613 vehicles and delivered 12,194, reaffirming its annual guidance of 65,000–70,000 deliveries. Facing competition from cheaper …

Why Viavi Solutions (VIAV) Is Up 20.7% After Strong Q4 Profit Beat And Revenue Guidance

Viavi Solutions (VIAV) saw a significant stock increase after reporting strong Q4 fiscal 2026 results with a profit beat and positive revenue guidance for Q1 fiscal 2027. Despite a full-year net loss, the improved quarterly profitability and outlook are attributed to growing demand from …

Viavi Solutions (VIAV) Following Earnings Beat And Guidance Has A Valuation Question

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Viavi Solutions (VIAV) has drawn fresh attention after reporting quarterly earnings and revenue that exceeded analyst estimates for the June 2026 quarter, along …

Viavi Solutions Inc (VIAV) (Q4 2026) Earnings Call Highlights: Record Revenue and Margin ...

This article first appeared on GuruFocus. Net Revenue: $443.1 million in Q4 FY2026, above guidance of $427-$437 million; up 8.9% sequentially and 52.5% year-over-year. Full Year Revenue: $1.518 billion for FY2026, up 40% year-over-year. Operating Margin: 24% in Q4 FY2026, above guidance of 22.2%-23.2%; …

Jubilant Ingrevia: What is behind its flat revenue?